Albireo Pharma Competitors and Similar CompaniesClear all
Albireo Pharma's competitors and similar companies include CTI BioPharma, GBT (Global Blood Therapeutics), Genexine and Renovion.
 Albireo Pharma Albireo, a biotechnology company, develops therapeutic drugs for gastrointestinal diseases. |  CTI BioPharma CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. |  GBT (Global Blood Therapeutics) GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. |  Genexine Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics. |  Renovion Renovion (formerly known as The Repairion Group) is a company that develops therapies for chronic inflammatory airway diseases. | |
Founding Date | Founding Date 2003 | Founding Date 1992 | Founding Date 2012 | Founding Date 1999 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Boston, US HQ Göteborg, SE | Locations Seattle, US HQ Köln, DE | Locations South San Francisco, US HQ Paris, FR Berlin, DE Baar, CH London, GB | Locations Seongnam-si, KR HQ New York, US | Locations Chapel Hill, US HQ |
Employees | Employees 5541% increase | Employees 2546% decrease | Employees 352106% increase | Employees 86 | Employees 5 |
Valuation ($) | Valuation ($) 915.9 m | Valuation ($) 1.2 b | Valuation ($) 4.4 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $40.6m (FY, 2021) | Revenue (est.) $53.9m (FY, 2022) | Revenue (est.) $194.7m (FY, 2021) | Revenue (est.) ₩4.6b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods $1.4m (FY, 2021) | Cost of goods $3.5m (FY, 2022) | Cost of goods $3.3m (FY, 2021) | Cost of goods (₩503.7m) (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit $39.2m (FY, 2021) | Gross profit $50.4m (FY, 2022) | Gross profit N/A | Gross profit ₩7.8b (FY, 2025) | Gross profit N/A |
Net income | Net income ($34m) (FY, 2021) | Net income ($93m) (FY, 2022) | Net income ($303.1m) (FY, 2021) | Net income (₩27.2b) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 40m | Total funding raised $ 105m | Total funding raised $ 88.7m | Total funding raised N/A | Total funding raised $ 14.4m |
For sources of this data, please see the company profile
View Company Profiles
CTI BioPharma
HQ
Seattle, US
Employees
25↓ 46% decrease
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers.
View companyGBT (Global Blood Therapeutics)
HQ
South San Francisco, US
Employees
352
GBT (Global Blood Therapeutics) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need.
View companyGenexine
HQ
Seongnam-si, KR
Employees
86
Genexine is a biotechnology company focused on the development and commercialization of immunotherapeutics and long-acting biologics.
View companyRenovion
HQ
Chapel Hill, US
Employees
5
Renovion (formerly known as The Repairion Group) is a company that develops therapies for chronic inflammatory airway diseases.
View company